key: cord-0957433-es1v37je
authors: Li, Rong; Liu, Jun; Zhang, Hui
title: The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development
date: 2021-04-20
journal: J Genet Genomics
DOI: 10.1016/j.jgg.2021.03.001
sha: 8e49ddfbbaf5f96018e81fa40c26927ce8762862
doc_id: 957433
cord_uid: es1v37je

nan

Asn 501 that participates in the interaction between RBD and ACE2 and the additional deletion at 69-70 position that could increase the capability (Leung et al., 2020) . As for its impact on pathogenicity, B.1.1.7 infection was correlated with a higher risk of lethality (Peter Horby et al., 2021) . Referring to the results of neutralization assays tittering the neutralizing antibodies (NAbs) against B.1.1.7 lineage from different reports, the mutations in the spike caused no significant reduction of neutralizing activity of plasma from convalescents who suffered COVID-19 in early 2020, suggesting that NAbs induced by the infection of original viral lineages could still maintain activity against B.1.1.7 variant Li et al., 2021; Rees-Spear et al., 2021) . Furthermore, most of the subsequent studies claimed that the mutations inside spike of B.1.1.7 have minor effects on immune evasion, although N501Y mutation could eliminate the binding affinity of class 3 NAbs that target the N terminal domain (NTD) of the spike .

The 501Y.V2 variant was first reported in Nelson Mandela Bay, South Africa in early October 2020. Similar to the B.1.1.7, 501Y.V2 variant was found to have robust transmissibility and rapidly became the dominant lineage over South Africa (> 90%) before December 2020 (Tegally et al., 2020) . It emerged in other countries like the US as well. Specific mutations including K417N, E484K, N501Y within RBD of 501Y.V2 increased its binding affinity with ACE2, while K417 and E484 of the dominant epitope within RBD, receptor binding motif (RBM), were actually not conserved and had plasticity to mutate to escape the interaction of related NAbs (Thomson et al., 2021; Wang et al., 2021) . These mutants were associated significantly with immune evasion. Especially, E484K was considered as one of the most important mutations that could lead to the insensitivity of NAbs (Liu et al., 2021a; Liu et al., 2021b) . The combination of K417N, E484K, and 242-244 deletion mutations could robustly impact three classes of NAbs, which may consequently reduce the neutralizing activity of sera from more than 90% early convalescents Wibmer et al., 2021) , while some of the samples showed a nearly 90% neutralization reduction (Greaney et al., 2021) . Although the enhancement of pathogenicity of 501Y.V2 was not verified with conclusive evidence, it has been shown that a mouse-adapted SARS-CoV-2 strain with alike mutation sites (N501Y, Q493H, and K417N) could induce severe organ damages similar to COVID-19 in mice, which showed higher lethality in the infected aged male mice (Sun et al., 2020) . More studies are needed to estimate the clinical risks of the 501Y.V2 variant.

The genomic sequence of P.1 lineage was first identified in Manaus, Brazil, which shared several mutation sites with 501Y.V2 including K417T, E484K, and N501Y. In the late December of 2020, P.1 lineage became dominant as nearly 40% of cases in Manaus confirmed this variant (Paola Cristina Resende et al., 2021) . Surprisingly, more than 75% of residents in this area were infected with SARS-CoV-2 previously (Buss et al., 2021) . These possible reinfection cases related to P.1 lineage alarm that the mutations within this variant may confer potent ability to escape the anti-SARS-CoV-2 immune memory established in the previous infection.

Besides these mutants listed above, several emerging variants with unclear risk were recently identified. The variant emerging in Southern California of the US harbored a mutation L452R within RBM, which has been reported to be resistant to NAbs and was defined as B.1.429 lineage . Another variant, B.1.525 detected first in the UK in December 2020, now becomes dominant in Nigeria (Hodcroft et al., 2021; WHO, 2021) . Mutations among the B.1.525 variant are partially similar to 501Y.V2 and B.1.1.7, respectively, which also include E484K and deletions within NTD. In addition, B.1.525 variant contains two other biologically significant mutations, Q677H and F888L. The risk of these new emerging mutants of concern still needs to be further estimated with more epidemiological and biological data.

Till February 7, 2021, analyses on vaccine protection against novel SARS-CoV-2 variants had been reported, including the analyses of RNA vaccines from Moderna and Pfizer (BNT162b2), protein subunit vaccine from Novavax and Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd, China, two adenovirus vaccines from Johnson & Johnson (JNJ) and AstraZeneca (AZN), and an inactivated virus vaccine from Beijing Institute of Biological Products (Beijing, China).

In the neutralization assays for the sera from participants vaccinated with BNT162b2, N501Y mutation within RBD, the most important region targeted by NAbs, had a slight impact on NAbs efficacy induced after vaccination. This result suggests that B.1.1.7 may not decrease the protective effect of BNT162b2, which could induce 7-fold higher NAb titers in comparison with the sera of COVID-19 convalescents (Muik et al., 2021; Tada et al., 2021) . Nevertheless, another study claimed that 144-145 deletion in the spike of B.1.1.7 may eliminate the efficacy of a potent class of NAbs that binds to the NTD of the spike, consequently reducing NAb titers for nearly 3.85 fold in some volunteers Collier et al., 2021) . The same slight reduction of neutralizing activity against live B.1.1.7 variant (and also N501Y single-mutated variant) occurred in the volunteers acquiring mRNA-1273 from Moderna company, which decreased 1-3 fold compared with the early-stage lineage (Edara et al., 2021) . Until the middle of March 2021, there was no detailed analysis of RNA vaccine efficacy reduction relating to B.1.1.7 or 501Y.V2 variants in clinical phase 3 trial, although in vitro studies showed that the neutralizing activity of plasma from RNA vaccinees may decrease against mutant variants, especially 501Y.V2 as the NAb titers of these plasma were reduced from 2.74 to 7.6 fold against 501Y.V2 and 1.22 fold against P.1 strain (Liu et al., 2021a; Zhou et al., 2021) . The E484K mutation may contribute mainly to this reduction since the neutralization assays against E484K single-mutated pseudotyped viruses showed a nearly 4.3-fold decrease in neutralizing activity (Jangra et al., 2021; Tada et al., 2021) . A similar J o u r n a l P r e -p r o o f reduction of NAb titers in the plasma of BNT162b2 and mRNA-1273 vaccine recipients was also detected against another variant, B.1.429, which contains E484K as well (Garcia-Beltran et al., 2021) . A recent study found that in some convalescents who had recovered from COVID-19 for 4-8 months and received a single-dose of RNA vaccine (from Pfizer or Moderna), immune memory was recalled rapidly. Although pre-vaccinated sera could barely neutralize 501Y.V2, the NAb titers were boosted for an approximate 1000-fold increase in the post-vaccinated sera, which is still lower than that against the wild-type early-stage strain (median titers, 5,156 versus 14,100) (Stamatatos et al., 2021) .

Novavax released the phase 3 trial results of NVX-CoV2373 on January 29, 2021, which were conducted in the UK and South Africa. In the UK, NVX-CoV2373 had a protective efficacy of 85.6% against B.1.1.7 lineage, which was slightly lower in comparison with the 95.6% efficacy against the SARS-CoV-2 early-stage strain. However, the results of South Africa phase 2b trial indicated that only 60% efficacy was observed in the HIV-negative population, while the overall efficacy fell to 49.4% if the statistics included HIV-positive subjects (Shinde et al., 2021) . Additionally, another study also found 1.3 to 2.5, and 1.1 to 3 fold decreases of neutralizing activity among NVX-CoV2373 vaccinated individuals against N501Y-containing and three mutations-containing (K417N, E484K, N501Y) pseudotyped viruses, respectively . Another recombinant vaccine, ZF2001, a dimeric RBD vaccine on phase 3 trial, could encouragingly induced robust neutralizing activity against live 501Y.V2 variant, while the titers were declined for only 1.6-fold compared with non-mutated strains (Huang et al., 2021) .

The first adenovirus-vectored vaccine in clinical phase III trial that reported their results of efficacy against 501Y.V2 variant was JNJ-manufactured Ad26.COV2.S vaccine on January 29, 2021 (Johnson&Johnson, 2021). After a single-dose vaccination, the overall protective efficacy of 66% in preventing moderate to severe COVID-19 has been reached. The trials were performed on different continents and the efficacy was 72%, 66%, and 57% in the US (cases included early-stage strain and B.1.1.7 variant), Latin America, and South Africa, respectively, which suggested that different efficacy may be correlated with immune evasion variants. Furthermore, it has been reported that 95% of COVID-19 cases from Ad26.COV2.S-receiving volunteers in South Africa were infected with the 501Y.V2 variant. Another phase II/III trial for the adenovirus-vectored vaccine, ChAdOx1 nCOV-19(AZD1222) from AstraZeneca and University of Oxford, had released a result of 66.7% overall efficacy. The in vitro results of sera neutralizing activity against live B.1.1.7 variant indicated that the vaccine-induced NAb titers were 9-fold lower than that against a canonical non-B.1.1.7 lineage. Nevertheless, the efficacy that prevented symptomatic COVID-19 was slightly lower for B.1.1.7 compared with non-B.1.1.7 lineage, which provided a potential correlation between in vitro neutralizing activity and overall J o u r n a l P r e -p r o o f efficacy (Voysey et al., 2021) . However, 501Y.V2 still showed robust resistance to vaccine-induced humoral immunity, against which 50% titres of focus reduction neutralization test (FRNT) decreased for nearly 9 fold among plasma from AZD1222 vaccinees (Zhou et al., 2021) .

Lately, an inactivated virus vaccine (BBIBP-CorV) was reported to have efficacy against the 501Y.V2 variant. In live virus neutralization assays, serum samples from BBIBP-CorV vaccine recipients were tested and found to neutralize HB02 (early-stage 614D strain), 614G strain, and 501Y.V2 variant with the mean titers of 110.9, 107.2, and 70.9, respectively, suggesting that the titers only decreased by 1.6 fold against 501Y.V2 variant (Huang et al., 2021) .

Given that in the UK, the primary B.1.1.7 lineage was recently identified to carry E484K mutation in a fraction of viral sequences (Wise et al., 2021) , it is rational to infer that E484K, which shared by 501Y.V2 and P1 variants independently, may appear as a similar tendency of immune evasion under immune pressure (Eguia et al., 2020) . Considering some studies reported that the NAb titers against viruses harboring this mutation have reduced and the efficacy of various vaccines had declined in epidemic areas of these variants, the strategies for developing vaccines against immune evasion variants are urgently needed to prevent new waves of pandemics due to the rapid emergence of viral mutants. This requirement is similar to the vaccine development strategies of influenza viruses, which frequently undergo mutation so that the vaccines targeting the viral variants are routinely generated.

The risk of the E484K mutation warns us to design and estimate new vaccine strategies that could rapidly respond to the dynamically evolving viruses. Alongside E484K, other mutation hotspots such as N501Y, K417N, and K417T should be included in the immunogen design. Multivalent immunogens containing different variants may confer potent and broader protective efficacy against frequently mutated viruses (Quan et al., 2008; Ma et al., 2020) .

In addition to updating the design of immunogen, the optimization of inoculation strategy would be another solution to deal with variants. In the mouse model, receiving heterologous two-dose vaccination including RNA and adenovirus-vectored vaccines induced higher titers of NAbs than either single-dose vaccination or two doses of adenovirus-vectored vaccine, along with superior cell immune response (Spencer et al., 2021) .

Importantly, if vaccines carrying mutations are demanded in case of spreading of immune evasive variants, the additional boosting dose, so-called "third dose", of updated vaccine could be inoculated to provide adequate protection, whether with a heterologous dose or homologous vaccine. Considering the plasma of convalescents exhibited poor neutralization ability against new variants, the populations who recovered from COVID-19 or asymptomatic infection should also be included in vaccine recipients, in which a more potent immune response would be induced due to the immune memory (Saadat et al., 2021) . Moreover, for those who are naïve to vaccination, a multivalent vaccine could be considered to be produced to improve efficacy and cover a wider range of variants.

COVID-19 pandemic emerged at the end of 2019 had caused more than 2.6 million death and billions of economic losses. Productive vaccine programs under accelerated studies and clinical trials indeed relieve the anxiety for possible upcoming of another "Spanish influenza" in the 21 st century. However, the problem that whether the evolution of the virus would run faster than the vaccine development still remains to be resolved. More studies, especially on structural analysis of immunogen, antibody-epitope interaction prediction, and the underlying mechanisms for both humoral and cellular immunity against SAR-CoV-2 infection, are quite necessary for vaccine design and vaccination strategy, which will be an important aspect in the next period of vaccine development.

Schematic of the full-length spike protein of SARS-CoV-2 variants, including G614, D614, B.1.1.7, 501Y.V2, and P.1 lineage. Mutations in the S protein of different variants are shown in yellow labeled with the precise position. NTD, N terminal domain. RBD, receptor binding domain. FP, fusion peptide. HR1, heptad repeat 1. HR2, heptad repeat 2.

J o u r n a l P r e -p r o o f

Three-quarters attack rate of SARS-CoV-2 in the Brazilian amazon during a largely unmitigated epidemic

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

A human coronavirus evolves antigenically to escape antibody immunity

Updated SARS-CoV-2 single nucleotide variants and mortality association

Emergence of SARS-CoV-2 B.1.1.7 lineage -United States

Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes

Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera

Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 virus

Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the united kingdom

The impact of mutations in SARS-CoV-2 Spike on viral infectivity and antigenicity

Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques

Neutralizing activity of BNT162b2-elicited serum

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil

NERVTAG: note on B.1.1.7 severity

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

The impact of spike mutations on SARS-CoV-2 neutralization

Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

Preliminary efficacy of the NVX-CoV2373 covid-19 vaccine against the B.1.351 variant

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2

Neutralization of viruses with european, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Transmission of SARS-CoV-2 lineage B.1.1.7 in england: Insights from linking epidemiological and genetic data

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Covid-19 weekly epidemiological update, Data as received by who from national authorities, as of 21 february 2021, 10 am cet. in COVID-19 Weekly Epidemiological Update World Health Organization

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Emergence of a novel SARS-CoV-2 variant in southern California

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera